Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value

por Ardeshna, Kirit M.
Publicado 2007

FLT PET-CT in evaluation of treatment response

por Sanghera, Bal, Wong, Wai Lup, Sonoda, Luke I, Beynon, Gwen, Makris, Andreas, Woolf, David, Ardeshna, Kirit
Publicado 2014

Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin’s and Diffuse Large B Cell Lymphomas

por Latifoltojar, Arash, Duncan, Mark K. J., Klusmann, Maria, Sidhu, Harbir, Bainbridge, Alan, Neriman, Deena, Fraioli, Francesco, Lambert, Jonathan, Ardeshna, Kirit M., Punwani, Shonit
Publicado 2020

Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRU...

por Townsend, William, Leong, Sarah, Hoskin, Peter, Diez, Patricia, Patrick, Pip, Linch, David, Wong, Wai‐Lup, Kayani, Irfan, Sanghera, Bal, Lopes, Andre, Daw, Stephen, Collins, Graham, Clifton‐Hadley, Laura, Ardeshna, Kirit
Publicado 2019

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for...

por Davies, Andrew, Barrans, Sharon, Burton, Cathy, Mercer, Katy, Caddy, Joshua, Chinnery, Fay, Day, Laura, Fernando, Diana, Ardeshna, Kirit, Collins, Graham, Radford, John, Rule, Simon, McMillan, Andrew, Johnson, Peter, Griffiths, Gareth
Publicado 2020

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

por Phillips, Elizabeth H., Burton, Catherine, Kirkwood, Amy A., Barrans, Sharon, Lawrie, Anthony, Rule, Simon, Patmore, Russell, Pettengell, Ruth, Ardeshna, Kirit M., Montoto, Silvia, Paneesha, Shankara, Clifton‐Hadley, Laura, Linch, David C., McMillan, Andrew K.
Publicado 2020

P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

por Caimi, Paolo F, Ai, Weiyun Z, Pablo Alderuccio, Juan, Ardeshna, Kirit M, Hamadani, Mehdi, Hess, Brian, Kahl, Brad S, Radford, John, Solh, Melhem, Stathis, Anastasios, Luigi Zinzani, Pier, Wang, Ying, Qin, Yajuan, Wang, Luqiang, Xu, Cindy, Carlo-Stella, Carmelo
Publicado 2023

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

por Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles
Publicado 2020

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report

por Mackenzie, Strachan, Shafat, Manar, Roddy, Harriet, Hyare, Harpreet, Neill, Lorna, Marzolini, Maria A. V., Gilhooley, Michael, Marafioti, Teresa, Kara, Eleanna, Sanchez, Emilie, Rees, Jeremy, Lynch, David S., Thomson, Kirsty, Ardeshna, Kirit M., Laurence, Arian, Peggs, Karl S., O'Reilly, Maeve, Roddie, Claire
Publicado 2021

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

por Alderuccio, Juan P., Ai, Weiyun Z., Radford, John, Solh, Melhem, Ardeshna, Kirit M., Lunning, Matthew A., Hess, Brian T., Zinzani, Pier L., Stathis, Anastasios, Carlo-Stella, Carmelo, Hamadani, Mehdi, Kahl, Brad S., Ungar, David, Kilavuz, Turk, Yu, Eric, Qin, Yajuan, Caimi, Paolo F.
Publicado 2022

The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study

por Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Szafer-Glusman, Edith, Eckert, Karl, Neuenburg, Jutta K., Goy, Andre
Publicado 2022

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

por Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M., McKay, Pamela, Leitch, Sophie, Coleman, Morton, Zinzani, Pier Luigi, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Browett, Peter, Ke, Xiaoyan, Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith
Publicado 2023

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

por Gleeson, Mary, Peckitt, Clare, To, Ye Mong, Edwards, Laurice, Oates, Jacqueline, Wotherspoon, Andrew, Attygalle, Ayoma D, Zerizer, Imene, Sharma, Bhupinder, Chua, Sue, Begum, Ruwaida, Chau, Ian, Johnson, Peter, Ardeshna, Kirit M, Hawkes, Eliza A, Macheta, Marian P, Collins, Graham P, Radford, John, Forbes, Adam, Hart, Alistair, Montoto, Silvia, McKay, Pamela, Benstead, Kim, Morley, Nicholas, Kalakonda, Nagesh, Hasan, Yasmin, Turner, Deborah, Cunningham, David
Publicado 2018

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

por Roddie, Claire, Lekakis, Lazaros J., Marzolini, Maria A. V., Ramakrishnan, Aravind, Zhang, Yiyun, Hu, Yanqing, Peddareddigari, Vijay G. R., Khokhar, Nushmia, Chen, Robert, Basilico, Silvia, Raymond, Meera, Vargas, Frederick Arce, Duffy, Kevin, Brugger, Wolfram, O’Reilly, Maeve A., Wood, Leigh, Linch, David C., Peggs, Karl S., Bachier, Carlos, Budde, Elizabeth Lihua, Lee Batlevi, Connie, Bartlett, Nancy, Irvine, David, Tholouli, Eleni, Osborne, Wendy, Ardeshna, Kirit M., Pule, Martin A.
Publicado 2023

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

por Opat, Stephen, Tedeschi, Alessandra, Linton, Kim, McKay, Pamela, Hu, Bei, Chan, Henry, Jin, Jie, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Coleman, Morton, Thieblemont, Catherine, Browett, Peter, Ke, Xiaoyan, Sun, Mingyuan, Marcus, Robert, Portell, Craig A., Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Mapp, Sally, Ho, Shir-Jing, Talaulikar, Dipti, Zhou, Ke-Shu, Co, Melannie, Li, Xiaotong, Zhou, Wenxiao, Cappellini, Massimo, Tankersley, Chris, Huang, Jane, Trotman, Judith
Publicado 2021

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

por Santarsieri, Anna, Sturgess, Katherine, Brice, Pauline, Menne, Tobias F., Osborne, Wendy, Creasey, Thomas, Ardeshna, Kirit M., Behan, Sarah, Bhuller, Kaljit, Booth, Stephen, Chavda, Nikesh, Collins, Graham P., Culligan, Dominic, Cwynarski, Kate, Davies, Andrew, Dutton, David, Furtado, Michelle, Gallop-Evans, Eve, Hodson, Andrew, Hopkins, David, Hsu, Hannah, Iyengar, Sunil, Jones, Stephen G., Linton, Kim, Lomas, Oliver, Martinez-Calle, Nicolas, Mathur, Abhinav, Mckay, Pamela, Nagumantry, Sateesh K., O’Mahony, Deidre, Phillips, Beth, Phillips, Neil, Rudge, John F., Shah, Nimish, Stafford, Gwyneth, Sternberg, Alex, Trickey, Rachel, Uttenthal, Benjamin J., Wetherall, Natasha, Mcmillan, Andrew K., Follows, George A.
Publicado 2022